CCM
ADPT icon

Cinctive Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

Cinctive Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-53,884
Closed -$748K – 414
2026
Q1 		$748K Buy
+53,884
New +$858K 0.05% 271
2025
Q4 		– Sell
-310,313
Closed -$4.64M – 388
2025
Q3 		$4.64M Sell
310,313
-305,431
-50% -$3.72M 0.22% 153
2025
Q2 		$7.17M Buy
615,744
+239,008
+63% +$2.17M 0.38% 88
2025
Q1 		$2.8M Buy
376,736
+135,420
+56% +$1.04M 0.21% 136
2024
Q4 		$1.45M Buy
+241,316
New +$1.33M 0.07% 258
2021
Q4 		– Sell
-43,797
Closed -$1.49M – 529
2021
Q3 		$1.49M Buy
+43,797
New +$1.58M 0.07% 343
2020
Q3 		– Sell
-43,267
Closed -$2.09M – 281
2020
Q2 		$2.09M Buy
+43,267
New +$1.58M 0.24% 179

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Cinctive Capital Management's ADPT Position: Q2 2026 in Review

Cinctive Capital Management sold out of Adaptive Biotechnologies (ADPT) in Q2 2026, closing a stake of 53,884 shares — an estimated $748K sold.

Cinctive Capital Management first reported a position in ADPT in Q2 2020 and held it in 7 quarters. The position peaked at $7.17M in Q2 2025. 301 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Cinctive Capital Management reported no remaining Adaptive Biotechnologies position as of Q2 2026 after selling out during the quarter.
  • Cinctive Capital Management sold 53,884 Adaptive Biotechnologies shares in Q2 2026, an estimated $748K.
  • Cinctive Capital Management first reported a position in Adaptive Biotechnologies in Q2 2020 and held it in 7 quarters.
  • Cinctive Capital Management's Adaptive Biotechnologies position peaked at $7.17M in Q2 2025.
  • 301 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Cinctive Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.